Elanco Animal Health Incorporated (NYSE:ELAN) Position Raised by Twinbeech Capital LP

Twinbeech Capital LP raised its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 878.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 914,775 shares of the company's stock after acquiring an additional 821,288 shares during the quarter. Twinbeech Capital LP owned approximately 0.19% of Elanco Animal Health worth $11,078,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. CoreCap Advisors LLC bought a new position in shares of Elanco Animal Health in the fourth quarter worth about $29,000. Jones Financial Companies Lllp lifted its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. raised its position in Elanco Animal Health by 221.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after purchasing an additional 3,411 shares in the last quarter. MRP Capital Investments LLC bought a new position in shares of Elanco Animal Health in the 4th quarter worth $61,000. Finally, Blue Trust Inc. raised its position in shares of Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after acquiring an additional 1,894 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Trading Down 0.1%

Elanco Animal Health stock traded down $0.01 during mid-day trading on Friday, hitting $12.66. The company's stock had a trading volume of 4,743,380 shares, compared to its average volume of 5,073,930. The firm has a market capitalization of $6.29 billion, a PE ratio of 31.66, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock's fifty day moving average is $10.34 and its two-hundred day moving average is $11.45.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's revenue was down 1.0% compared to the same quarter last year. During the same period last year, the business posted $0.34 earnings per share. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction dated Tuesday, March 11th. The shares were acquired at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the transaction, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This trade represents a 9.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ELAN shares. Piper Sandler reduced their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Stifel Nicolaus increased their target price on Elanco Animal Health from $15.00 to $16.00 and gave the company a "buy" rating in a report on Monday, May 19th. UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Finally, Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.